CNS Pharmaceuticals Corp - נכסים נקיים למניה בודדת CNSP

The GURU.Markets terminal provides the book value per share trend, where 12.35 indicates the value of this parameter. CNS Pharmaceuticals (CNSP) is accelerating the market launch of Berubicin through partnerships with Western clinics. Targeted drug development in the US is focused on overcoming the blood-brain barrier. The company is currently in the research stage with no current revenue, relying on the issuance of securities.

Developing monopoly drugs for the treatment of brain cancer requires colossal capital expenditures, which directly form the net asset base of CNS Pharmaceuticals (CNSP). The book value per share trend reflects the difference between all assets and liabilities per share, allowing investors to assess the real value of CNS Pharmaceuticals (CNSP) without accounting for market speculation and price volatility.